SAN DIEGO, March 7, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the full year and fourth quarter ended December 31, 2012, on Wednesday, March 13, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 34404715. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
McDavid Stilwell
Vice President, Corporate Communications & Business Development
+1-858-875-8600
SOURCE Orexigen Therapeutics, Inc.
.is(':checked'))MM_swapImgRestore(); else MM_swapImage('Checkbox1','','http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif',1);void($('#emailMe').attr('checked', !$('#emailMe').is(':checked')))){kind=small}
News More...
| Orex Minerals, Inc. | View rex Stock Quote | |||
| Orex Exploration Inc. | View ox Stock Quote | |||
| Orexigen Therapeutics, Inc. | View orex Stock Quote | |||
| Orexigen Therapeutics, Inc. | View orex Stock Quote | |||
| Start Premium Trial | Register For Free |
| P | F | Fund Financial Data (13,000+ funds) |
| P | F | Stock Financial Data (7,000+ stocks) |
| P | F | Stock and Fund Screeners (basic) |
| P | F | Investing Articles and Market Commentary |
| P | F | Articles Archive (>30 days) |
| P | F | Discuss (dozens of stock, fund, bond, and general bulletin boards) |
| P | F | Portfolio Manager (basic) |
| P | F | Morningstar Investment Classroom |
| P | F | Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise) |
| P | Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs) | |
| P | Morningstar Stock Analyst Reports (full research on 2,000 stocks) | |
| P | Morningstar Stock and Fund Stewardship Grades | |
| P | Portfolio Manager (advanced with 10 x-ray analyses, including guidance) | |
| P | Portfolio Monitor (monthly and on-demand personalized portfolio statements) | |
| P | Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more) | |
| P | Morningstar Stock and Fund Favorites & Red Flags eNewsletters | |
| P | Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you) | |
| P | Discounts on Morningstar newsletters, books, seminars, and more |